WO2026043651 - COMPOSITION AND METHOD FOR TREATING ARTHRITIS
National phase entry is expected:
Publication Number
WO/2026/043651
Publication Date
26.02.2026
International Application No.
PCT/US2025/041039
International Filing Date
07.08.2025
Title **
[English]
COMPOSITION AND METHOD FOR TREATING ARTHRITIS
[French]
COMPOSITION ET PROCÉDÉ DE TRAITEMENT DE L'ARTHRITE
Applicants **
BORDOLOI BIOTECH LLC
Inventors
BORDOLOI, Binoy
BORDOLOI, Ronen
HEENEY, Nicole
MEHTA, Deepa
SAINI, Kulwant
SAIKIA, Debojit
Priority Data
18/813,748
23.08.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2088 | |
| EPO | Filing, Examination, Granting | 11648 | |
| Japan | Filing, Examination, Granting | 2091 | |
| South Korea | Filing, Examination, Granting | 2004 | |
| USA | Filing, Examination, Granting | 4310 |
Total:
22,141
Contact Us
Abstract[English]
, respectively. Both individual and binary blend exhibits downregulation of pro-inflammatory cytokines IL-2, IL-6, and TNF-α, and upregulation of anti-inflammatory cytokine IL-10[French]
, respectivement. Le mélange individuel et binaire présente à la fois une régulation à la baisse des cytokines pro-inflammatoires IL-2, IL-6 et TNF-α, et une régulation à la hausse de la cytokine anti-inflammatoire IL-10.